Zotiraciclib is a multi-kinase inhibitor that can be taken orally. A previous Phase 1 study showed zotiraciclib may be effective in people with recurrent gliomas containing mutations in the IDH1 or IDH2 genes. I like this trial because there is no placebo group; the trial team will use a matched external control group instead.